INTRODUCTION
============

Tuberous sclerosis complex (TSC) is an autosomal dominantly inherited neurocutaneous disorder affecting approximately 1 million individuals worldwide ([@nlaa040-B1],[@nlaa040-B2]). It is caused by inactivating mutations in either the *TSC1* or the *TSC2* gene ([@nlaa040-B3],[@nlaa040-B4]) resulting in constitutive activation of the mammalian target of rapamycin (mTOR) pathway which can affect cell growth and proliferation ([@nlaa040-B5]). Several brain abnormalities are observed in patients with TSC, including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas (SEGA) ([@nlaa040-B9]). SEGA are progressive low-grade tumors that develop in the first 2 decades of life in children and adolescents with TSC with a prevalence ranging from 5% to 25% ([@nlaa040-B12]). They are slow-growing tumors located near the foramen of Monro and extended growth can lead to the obstruction of the cerebrospinal fluid flow and acute hydrocephalus ([@nlaa040-B16],[@nlaa040-B17]). Symptoms associated with growing SEGA include headaches, photophobia, diplopia, ataxia, or changes in seizure severity ([@nlaa040-B18]). SEGA are believed to develop from subependymal nodules and are characterized by distinctive cytomegalic cells, which display an immature neuroglial phenotype ([@nlaa040-B19]).

Genetically, there is evidence of second-hit inactivation of *TSC1* or *TSC2* in SEGA. However, in ∼20% of SEGA these second-hit mutations are not observed, suggesting that additional molecular processes might be involved in SEGA growth ([@nlaa040-B6],[@nlaa040-B23],[@nlaa040-B24]). Several studies have performed transcriptional profiling of SEGA identifying differential expression of genes related to the immune system, MAPK family signaling cascades and extracellular matrix (ECM) organization ([@nlaa040-B24]). Dysregulation of ECM organization has also been seen in TSC cortical tubers with a specific role for matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs), suggesting that the ECM might play an important role in TSC ([@nlaa040-B27]). MMPs are calcium-dependent zinc-containing endopeptidases that are expressed with a propeptide that needs to be removed for activation ([@nlaa040-B30]). TIMPs are "wedge-like"-shaped molecules with 4 residues at N-terminal that form a ridge that can noncovalently bind to the active site of MMPs and thereby inactivate them ([@nlaa040-B31]). The MMP/TIMP proteolytic system is known to be involved in the degradation of ECM ([@nlaa040-B32]), tissue morphogenesis ([@nlaa040-B33]), cell migration ([@nlaa040-B34]), angiogenesis ([@nlaa040-B35]), blood-brain barrier (BBB) dysfunction ([@nlaa040-B36]), wound healing and inflammation ([@nlaa040-B37]). Differential expression of MMPs is found in many pathologies including cancer, where they affect proliferation and the metastasis of tumor cells ([@nlaa040-B38]).

Several MMP inhibitors exist that can regulate MMP overactivity. However, the currently available MMP inhibitors can have a variety of side effects indicating the complexity of MMP regulation ([@nlaa040-B41]). MicroRNAs (miRNAs) are short noncoding RNAs which are 20--25 nucleotides long and are able to regulate the expression of protein-coding genes, including *MMPs* ([@nlaa040-B42],[@nlaa040-B43]). They are involved in many physiological processes, such as differentiation, proliferation, and development ([@nlaa040-B44]) and have been implicated in neurological disorders ([@nlaa040-B45],[@nlaa040-B46]). Previous research showed several miRNAs to be differentially expressed in TSC cortical tubers and SEGA ([@nlaa040-B26],[@nlaa040-B28],[@nlaa040-B29],[@nlaa040-B47],[@nlaa040-B48]). In particular, miRNAs have been shown to participate in MMP regulation at the post-transcriptional level in TSC tuber-derived astroglial cultures and glioma cell lines ([@nlaa040-B28],[@nlaa040-B49],[@nlaa040-B50]).

In our previous SEGA transcriptome study, we identified differential expression of genes related to several pathways including ECM organization, but did not further study the role of the ECM in SEGA in detail ([@nlaa040-B26]). As MMPs and TIMPs may contribute to TSC pathology and cancer, understanding their role in SEGA development could provide new insights into the SEGA biological behavior and potential new therapeutic targets. Therefore, in this study we investigated the expression of MMPs and TIMPs in SEGA. Furthermore, we identified differentially expressed miRNAs in SEGA compared to control tissue that could regulate the expression of MMPs and further investigated the role of these miRNAs in SEGA and their regulation of MMP expression in vitro.

MATERIALS AND METHODS
=====================

Subjects
--------

A total of 24 SEGA specimens (male/female: 16/8; age ranging from 1 to 28 years; ethnicity: Caucasian) were collected from the following hospitals: University Medical Centers Amsterdam (location Academic Medical Center, Amsterdam, the Netherlands), the University Medical Center Utrecht (Utrecht, the Netherlands), University Medical Center Groningen (Groningen, the Netherlands), Medical University of Vienna (Vienna, Austria), Children's Memorial Health Institute (Warsaw, Poland), Anna Meyer Children's Hospital (Florence, Italy) ([Table 1](#nlaa040-T1){ref-type="table"}). Twenty-two of the 24 SEGA samples included in this study were obtained from patients who met the clinical diagnostic criteria for TSC, whereas 2 samples were obtained from patients with no other clinical signs of TSC. Histological diagnosis was confirmed following the current WHO classification guidelines ([@nlaa040-B51]) by 2 independent neuropathologists. Additional *TSC1*/*TSC2* mutation analysis was performed as part of routine clinical care on blood or tumor sample DNA or was determined using massively parallel sequencing as described previously ([@nlaa040-B23],[@nlaa040-B52]), if available ([Table 1](#nlaa040-T1){ref-type="table"}). Periventricular brain tissue along the lateral ventricle at the level of either the caudothalamic groove or hippocampus plus its associated cortex was obtained from autopsies of patients (postmortem delay less than 24 hours) who did not have TSC, epilepsy or brain tumors and served as control tissue (frozen: n = 8, male/female: 6/2; age ranging from 3 to 87 years; paraffin: n = 4, male/female: 1/3; age ranging from 2 months to 44 years). Specimens were obtained and used in accordance with the Declaration of Helsinki and this study was approved by the Medical Ethics Committee of each institution.

###### 

Summary of Clinicopathological Features of Patients With SEGA

  SEGA No.    Age (Years)   Gender   Mutation   Location of Tumor   Epilepsy   Age of Epilepsy Onset   Seizure Frequency   AED[\*](#tblfn2){ref-type="table-fn"}   Tumor Size (mm)   Tumor Recurrence/Regrowth   mTOR Inhibitors      Other Clinical Manifestations
  ----------- ------------- -------- ---------- ------------------- ---------- ----------------------- ------------------- --------------------------------------- ----------------- --------------------------- -------------------- ------------------------------------------------------------------------------------
  1^a^        10            Male     *TSC2*     Lateral ventricle   Yes        3 years                 Daily               Yes                                     42                No                          No                   Unknown
  2^a^        11            Female   *TSC2*     Lateral ventricle   No         NA                      NA                  NA                                      Unknown           No                          No                   No other signs for TSC
  3^a,b,c^    8             Male     *TSC2*     Lateral ventricle   Yes        4 months                None                Yes                                     31                No                          No                   Cortical tuber, AML
  4^a^        13            Female   *TSC1*     Lateral ventricle   Yes        17 months               Monthly             Yes                                     40                No                          No                   Cortical tuber
  5^a^        1             Male     *TSC2*     Lateral ventricle   Yes        1 month                 Daily               Yes                                     30                No                          Yes (nonresponder)   Multiple SEGAs, cortical tubers, drug resistant epilepsy
  6^a,b^      13            Male     *TSC2*     Caudate nucleus     Yes        6 months                Weekly              Yes                                     20                No                          Yes (responder)      Tubers, minor psychomotor delay, SEN
  7^a^        14            Male     *TSC2*     Lateral ventricle   No         NA                      NA                  NA                                      5                 No                          No                   Renal cysts
  8^a^        4             Male     *TSC1*     Lateral ventricle   Yes        3 months                Monthly             Yes                                     5                 Yes                         No                   Cortical tuber
  9^a,b^      7             Female   *TSC2*     Lateral ventricle   Yes        5 months                Daily               Yes                                     45                No                          No                   Unknown
  10^a,b,c^   17            Female   *TSC2*     Lateral ventricle   No         NA                      NA                  NA                                      27                No                          No                   No other signs for TSC
  11^a^       1             Female   *TSC2*     Lateral ventricle   Yes        1 month                 Daily               Yes                                     30                No                          No                   Cortical tuber
  12^a,b,c^   13            Male     *TSC2*     Lateral ventricle   Yes        4 months                Weekly              Yes                                     20                Yes                         No                   Cortical tuber
  13^a,b^     24            Male     *TSC1*     Lateral ventricle   Yes        6 years                 Daily               Yes                                     40                No                          No                   Unknown
  14^a,b^     8             Male     NMI        Caudate nucleus     Yes        1 year                  Weekly              Yes                                     30                No                          No                   Minor psychomotor delay
  15^a^       9             Male     *TSC1*     Caudate nucleus     Yes        2 years                 Monthly             Yes                                     30                No                          No                   None
  16^a^       28            Female   *TSC2*     Unknown             Yes        Unknown                 Unknown             NA                                      Unknown           Unknown                     No                   Cortical tuber
  17^a,b,d^   33            Male     *TSC2*     Basal nuclei        Yes        6 months                Daily               Yes                                     30                Yes                         No                   Cortical tubers, autism, drug resistant epilepsy, behavior problems (aggressivity)
  18^a,b^     1             Male     *TSC2*     Caudate nucleus     Yes        8 months                Monthly             Yes                                     20                No                          No                   Minor psychomotor delay, cortical tubers
  19^a,b^     28            Male     *TSC2*     Lateral ventricle   Yes        7 years                 Daily               Yes                                     34                Yes                         No                   Unknown
  20^b,c^     1             Female   *TSC2*     Lateral ventricle   No         NA                      NA                  NA                                      20                No                          No                   Cortical tuber
  21^b,c,d^   4             Male     *TSC2*     Lateral ventricle   Yes        3 months                Daily               Yes                                     18                No                          No                   Cortical tuber, AML, autism
  22^c,d^     16            Male     *TSC1*     Lateral ventricle   No         NA                      NA                  NA                                      37                No                          No                   SEN
  23^c^       10            Male     *TSC2*     3th ventricle       Yes        3 months                Seizure free        Yes                                     60                No                          No                   Cortical tuber, AML, autism
  24^c^       5             Female   *TSC2*     Lateral ventricle   Yes        1 month                 Daily               Yes                                     66                No                          No                   Cortical tuber, AML, autism, FCD

SEGA samples used for RNA-Sequencing (a), RT-qPCR (b), in situ hybridization (c), and immunohistochemistry (d).

The most commonly used AEDs are carbamazepine, vigabatrin, valproate, and topiramate, however each patient had a personalized drug treatment regime.

AED, antiepileptic drugs; AML, angiomyolipoma; FCD, focal cortical dysplasia; NA, not applicable; NMI, no mutation identified; SEGA, subependymal giant cell astrocytomas; SEN, subependymal nodule; TSC, tuberous sclerosis complex.

RNA-Sequencing
--------------

RNA-Sequencing (RNA-Seq) data sets produced by our laboratory, were retrieved from the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG (accession number: EGAS00001003787) ([@nlaa040-B26]). Data were retrieved for 19 SEGA samples and 8 control and processed as previously described ([@nlaa040-B26]). Briefly, sequence reads were trimmed and filtered using FastQC v0.11.5 (Babraham Institute, Babraham, Cambridgeshire, UK) and Trimmomatic v0.36. Paired-end reads were aligned to the human reference genome (GRCh38) with TopHat2 v2.0.13 and default settings ([@nlaa040-B53]). For the small RNA-Seq data set no mismatches were allowed between the trimmed reads and the reference genome and small RNA reads were allowed to align a maximum of 10 times. Next, the number of reads that mapped to each gene, based on Gencode v25, was determined using featureCounts from the SubRead package ([@nlaa040-B54]). The count matrix was normalized using the R package DESeq2 ([@nlaa040-B55]). Genes and small RNAs with a Benjamini-Hochberg adjusted p value \< 0.05 were considered differentially expressed. Differentially expressed genes (DEGs) related to the ECM organization were identified by overlapping the ECM organization genelist from the Reactome database with the DEGs produced from the RNA-Seq data ([@nlaa040-B56],[@nlaa040-B57]).

To identify miRNAs that could potentially target all 5 *MMP* genes with a higher expression in SEGA compared to control (*MMP2*, *MMP11*, *MMP14*, *MMP15*, and *MMP19*), miRNAs that had lower expression in SEGA (adjusted p value \< 0.05) as compared to control and whose expression patterns where inversely correlated with *MMP* expression were selected. The list of predicted miRNA targets for each of the differentially expressed miRNAs was retrieved from miRWalk2 ([@nlaa040-B58],[@nlaa040-B59]). miRNAs that were predicted to target all 5 MMPs (*MMP2*, *MMP11*, *MMP14*, *MMP15*, and *MMP19*), were considered potential regulators of MMP expression.

RNA Isolation and Real-Time Quantitative PCR Analysis
-----------------------------------------------------

For RNA isolation, cell culture or fresh brain material (12 SEGA samples and 8 control samples) was homogenized in Qiazol Lysis Reagent (Qiagen Benelux, Venlo, The Netherlands). RNA was isolated using the miRNeasy Mini kit (Qiagen Benelux, Venlo, The Netherlands) according to manufacturer's instructions. The concentration and purity of RNA were determined at 260/280 nm using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). mRNA and miRNA expression was evaluated as described previously ([@nlaa040-B60]). Briefly, 250 ng of RNA were reverse-transcribed into cDNA using oligo dT primers. Real-time quantitative PCRs (RT-qPCR) were run according to the manufacturer's guidelines, on a Roche Lightcycler 480 thermocycler (Roche Applied Science, Basel, Switzerland) using LightCycler 480 SYBR Green I Master (Roche Applied Science, Indianapolis, IN) with the following cycling conditions: initial denaturation at 95°C for 5 minutes, followed by 50 cycles of denaturation at 95°C for 10 seconds, 65°C for 10 seconds, and 72°C for 15 seconds, annealing at 95°C for 5 seconds followed by extension on 65°C for 1 minute. PCR primers were designed using Universal Probe library (ProbeFinder version 2.53 for human, Roche Applied Science) ([Table 2](#nlaa040-T2){ref-type="table"}). Expression of miRNAs was analyzed using TaqMan microRNA assays (Applied Biosystems, Foster City, CA). cDNA was generated from 50 ng of RNA using TaqMan MicroRNA reverse transcription kit (Applied Biosystems). RT-qPCR was performed on a Lightcycler 480 Real-Time PCR System (Roche Applied Science). Quantification of the data was done using the LinRegPCR program in which linear regression on the Log(fluorescence) per cycle number data is applied to determine the amplification efficiency per sample ([@nlaa040-B61]). The expression of each specific product was divided by the geometric mean of the concentration of 2 reference genes (mRNA: Elongation factor 1-alpha \[*EF1α*\] and glyceraldehyde-3-phosphate dehydrogenase \[*GAPDH*\]; miRNA: the U6B small nuclear RNA gene \[RNU6B\] and RNU44).

###### 

Primer List

  Gene      Forward (5′-\>3′)        Reverse (5′-\>3′)
  --------- ------------------------ --------------------------
  *MMP2*    ATAACCTGGATGCCGTCGT      AGGCACCCTTGAAGAAGTAGC
  *MMP11*   TCCTGAGGTCAGGTCTTGGT     CAGATTTCCAGGATTGTCAGC
  *MMP14*   GCCTTGGACTGTCAGGAATG     AGGGGTCACTGGAATGCTC
  *MMP15*   CAGGCCCATCAGTGTCTGG      TGGTGCCCTTGTAGAAGTAGG
  *MMP16*   AGGGCATCCAGAAGATATATGG   GGCACTGTCGGTAGAGGTCTT
  *MMP17*   AAGAGGAACCTGTCGTGGAG     CACCTCGTGGAAGTTCAGG
  *MMP19*   ATGCCAGACCCTTGCAGTAG     CCCCCTTGAAAGCATAGGTC
  *MMP25*   TCCTGGGTGGTGGAATCA       GCAACGGAAAAGGTTAACAGC
  *TIMP1*   GGGCTTCACCAAGACCTACA     TGCAGGGGATGGATAAACAG
  *TIMP2*   TGCAGATGTAGTGATCAGGGC    TCTCAGGCCCTTTGAACATC
  *TIMP3*   GCTGGAGGTCAACAAGTACCA    CACAGCCCCGTGTACATCT
  *TIMP4*   TTGGTGCAGAGGGAAAGTCT     GGTACTGTGTAGCAGGTGGTGA
  *EF1α*    ATCCACCTTTGGGTCGCTTT     CCGCAACTGTCTGTCTCATATCAC
  *GAPDH*   AGGCAACTAGGATGGTGTGG     TTGATTTTGGAGGGATCTCG

Immunohistochemistry
--------------------

Sections were deparaffinated in xylene (3x) and rinsed in ethanol (100%, 95%, and 70%). Antigen retrieval was performed by incubating the sections in 0.1 M sodium citrate buffer pH 6.0 at 121°C for 10 minutes using a pressure cooker. Sections were washed with phosphate buffered saline (\[PBS\], pH 7.4) after which they were blocked with 10% normal goat serum (NGS) for 30 minutes at room temperature. After removal of NGS, primary antibody (1:200 rabbit polyclonal IgG anti-MMP2, Abcam, Cambridge, UK; 1:500 mouse monoclonal IgG 3/κ anti-MMP14, Merck, Darmstadt, Germany) in Normal Antibody Diluent (Immunological, Duiven, The Netherlands) was added to the sections and incubated overnight at 4°C. After incubation with primary antibodies, sections were washed in PBS and stained with a polymer-based peroxidase immunohistochemistry detection kit according to manufacturer's guidelines (PowerVision Peroxidase system, ImmunoVision, Brisbane, CA). After washing, sections were stained with 3,3′-diaminobenzidine tetrahydrochloride (50 mg diaminobenzidine \[DAB\], Sigma-Aldrich, Zwijndrecht, the Netherlands) and H~2~O~2~ in Tris-HCl (0.015% final concentration). The reaction was stopped by washing with dH~2~O, the sections were then counterstained with hematoxylin and dehydrated with ethanol (70%, 95%, 100%) and xylene (3x) and coverslipped.

Stainings of MMPs were quantified by measuring the optical density (OD) of SEGA and control tissue using ImageJ. For each case, 2-3 representative photographs of periventricular white matter (wm) (n = 4) and when present nearby gray matter (gm) (n = 3) were taken (20x magnification). Three OD measurements were taken after hematoxylin-DAB color deconvolution for each respective picture. Finally, the mean OD was calculated per case.

In Situ Hybridization
---------------------

Paraffin slides from SEGA and autopsy controls ([Table 1](#nlaa040-T1){ref-type="table"}) were deparaffinated in xylene (3x) and rinsed in ethanol (2x 100%, 70%) and dH~2~O. Sections were pretreated using a pressure cooker in 0.1 M sodium citrate buffer, pH 6.0, at 121°C for 10 minutes. The oligonucleotide probe for miR-320d (TCCTCUCAACCCAGCTUUT) contained LNA modification, 2-o-methyl modification and digoxigenin (DIG) label (RiboTask ApS, Odense, Denmark). Sections were incubated with the probe (1:750 dilution) in hybridization mix (600 mM NaCl, 10 mM HEPES, 1 mM EDTA, 5× Denhardts, 50% formamide) for 1 hour at 56°C. Sections were washed with saline-sodium citrate (SSC) 2× for 2 minutes, SSC 0.5× for 2 minutes, and SSC 0.2× for 1 minute (in agitation). After washing with sterile PBS, sections were blocked for 15 minutes with 0.02% Tween 20 and 1% NGS. Hybridization was detected with AP labeled with anti-DIG (Roche Applied Science, Basel, Switzerland). Nitro-blue tetrazolium chloride/5-bromo-4-chloro-3′-indolyphosphate p-toluidine salt was used as chromogenic substrate for AP (1:50 diluted in NTM-T buffer \[100 mM Tris, pH 9.5; 100 mM NaCl; 50 mM MgCl~2~\]; 0.05% Tween 20). Expression of miR-320d was quantified by measuring the OD of SEGA and control tissue using ImageJ. For each case, 2 and 3 representative photographs of periventricular wm (n = 9) and when present nearby gm (n = 7) were taken (20x magnification). Three OD measurements were taken for each respective picture. Finally, the mean OD was calculated per case.

Cell Culture
------------

As SEGA are thought to originate from neuroglial precursor cells that undergo an altered/impaired development, we have chosen to use a glial cell type in a developmental state; (human fetal astrocyte-enriched cells) to study the role of miR-320d on MMP expression under basal conditions. Primary fetal astrocyte-enriched cell cultures were obtained from fetal brain tissue (n = 3, 14--19 weeks of gestation) collected from medically induced abortions as described previously ([@nlaa040-B47],[@nlaa040-B48]), with appropriate maternal written consent for brain autopsy. Briefly, blood vessels were removed and the tissue was cut into smaller fragments. The tissue was enzymatically digested by incubating at 37°C for 30 minutes with trypsin. The enzymatic reaction was stopped by adding twice the amount of astrocyte medium (DMEM/F10, 10% FCS, 5% penicillin/streptomycin, and 5% glutamine) and the cell suspension was passed through a 70-µm cell strainer. After washing 2 times with astrocyte medium, the cells were incubated at 37°C, 5% CO~2~ for 48 hours after which they were thoroughly washed with PBS. Fresh medium was added twice a week and cultures reached confluency after 2 and 3 weeks. Secondary astrocyte cultures for experimental manipulation were established by trypsinizing confluent cultures and subplating onto poly-[l]{.smallcaps}-lysine (PLL; 15 mg/mL, Sigma-Aldrich, St. Louis, MO)-precoated 6- and 12-well plates (Costar; 50 000 cells/well in a 12-well plate for RNA isolation and RT-qPCR).

Transfection of Cell Cultures
-----------------------------

Cells on PLL-coated plates were transfected with mimic pre-miRNA for hsa-miR-320d (50 µM; Applied Biosystems, Carlsbad, CA) for 24 hours. Cells treated with lipofectamine without mimic were used as a control. Mimics were delivered to the cells using Lipofectamine 2000 transfection reagent (Life Technologies, Grand Island, NY) in a final concentration of 50 nM.

Statistical Analysis
--------------------

Statistical analyses were performed with GraphPad Prism version 5 (GraphPad Software, La Jolla, CA) and IBM SPSS Statistics 24 (IBM Corp., Armonk, NY) using the nonparametric Mann-Whitney U test or, for multiple groups, the nonparametric Kruskal-Wallis test followed by Mann-Whitney U test. A p value \< 0.05 was assumed to indicate a statistical difference. Correlations were assessed with R or IBM SPSS Statistics 24, using the Spearman's rank correlation test (p \< 0.05 and 0.7 \< r \> −0.7 was considered statistically significant).

RESULTS
=======

*MMP* and *TIMP* Expression in SEGA
-----------------------------------

RNA-Seq data previously produced by our laboratory was used to specifically investigate the expression of *MMPs* and *TIMPs* in SEGA ([@nlaa040-B26]). In total, 19 surgical SEGA samples (obtained from 17 TSC patients and 2 patients without any clinical signs of TSC) and 8 area-matched periventricular controls (autopsy specimens) without a history of other neurological diseases were subjected to RNA-Seq ([@nlaa040-B26]) ([Table 1](#nlaa040-T1){ref-type="table"}). Differential gene expression analysis identified 4621 genes overexpressed and 4779 underexpressed (adjusted p value \< 0.05) in SEGA samples compared to control tissue, of which 133 genes belong to the Reactome-based ECM organization pathway ([Fig. 1A](#nlaa040-F1){ref-type="fig"}). Furthermore, the gene expression of these 133 genes could be used to separate the control and SEGA samples ([Fig. 1B](#nlaa040-F1){ref-type="fig"}). Among the 133 genes identified *MMP2*, *MMP11*, *MMP14*, *MMP15*, *MMP16*, *MMP17*, *MMP19*, *MMP25*, *TIMP1* and *TIMP2* were differentially expressed ([Fig. 1A, B](#nlaa040-F1){ref-type="fig"}). Though not present in the ECM organization pathway, the other 2 TIMPs found in the brain, *TIMP3* and *TIMP4*, were also among the 9400 DEGs ([Table 3](#nlaa040-T3){ref-type="table"}). These MMPs and TIMPs were selected for further validation with RT-qPCR. Higher expression of *MMP2*, *MMP11*, *MMP14*, *MMP15*, *MMP19*, *TIMP1*, *TIMP2*, and *TIMP3* was found in SEGA (n = 12) as compared to control tissue (n = 8; p \< 0.05; [Fig. 2A--H](#nlaa040-F2){ref-type="fig"}). The expression of *MMP17* ([Fig. 2I](#nlaa040-F2){ref-type="fig"}) was lower in SEGA as compared to control tissue, whereas *MMP16*, *MMP25*, and *TIMP4* expression did not change ([Fig. 2J--L](#nlaa040-F2){ref-type="fig"}). RNA expression of *MMPs* and *TIMPs* did not correlate with the age at epilepsy onset, age at surgery, or size of the tumor (p \> 0.05 and −0.7 \< r \> 0.7 for both RT-qPCR and RNA-Seq data). Furthermore, RNA expression of *MMPs* and *TIMPs* was not associated with the clinical features such as gender, TSC mutation, epilepsy, or preoperative seizure frequency (Mann-Whitney U test or, for multiple groups, the nonparametric Kruskal-Wallis test; p \> 0.05 for both RT-qPCR and RNA-Seq data). *MMP19* expression based on the RT-qPCR was higher in recurrent/regrown SEGA compared to nonrecurrent/regrown SEGA ([Supplementary Data](#sup1){ref-type="supplementary-material"}[Fig. S1](#sup1){ref-type="supplementary-material"}; p = 0.0485). However, RNA-Seq data did not show differences between recurrent/regrown SEGA and nonrecurrent/regrown SEGA (p = 0.96).

![The extracellular matrix (ECM) organization in subependymal giant cell astrocytomas (SEGA). (**A)** Volcano plot showing the differentially expressed genes (\[DEGs\]; adjusted p value \< 0.05; light gray) between SEGA and control tissue. A total of 4621 mRNAs were found to be overexpressed and 4779 underexpressed in SEGA (n = 19) as compared to control tissue (n = 8). A total of 133 DEGs were related to the Reactome-based ECM organization pathway (dark gray). Among the 133 genes *MMP2*, *MMP11*, *MMP14*, *MMP15*, *MMP19*, *TIMP1*, *TIMP2* were overexpressed and *MMP16*, *MMP17* and *MMP25* were underexpressed. **(B)** Heatmap with Z-score hierarchical clustering for the RNA expression data of DEGs related to the Reactome-based ECM organization pathway in SEGA (n = 19) and control tissue (n = 8). The color scale means the gene expression standard deviations from the mean, with green for low expression and red for the high expression.](nlaa040f1){#nlaa040-F1}

![Gene expression *MMPs* and *TIMPs* differentially expression in subependymal giant cell astrocytomas (SEGA) compared to controls. **(A--L)** Gene expression was studied using RT-qPCR analysis of *MMP2* **(A)**, *MMP11* **(B)**, *MMP14* **(C)**, *MMP15* **(D)**, *MMP19* **(E)**, *TIMP1* **(F)**, *TIMP2* **(G)**, *TIMP3* **(H)**, *MMP17* **(I)**, *MMP16* **(J)**, *MMP25* **(K)**, TIMP4 **(L)** in SEGA (n = 12) and controls (n = 8). Data are expressed relative to the expression observed in control tissue. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, Mann-Whitney U test.](nlaa040f2){#nlaa040-F2}

###### 

Differentially Expressed MMPs and TIMPs in SEGAs as Compared to Control Tissue

  mRNA               *MMP2*     *MMP11*   *MMP14*    *MMP15*   *MMP16*   *MMP17*   *MMP19*   *MMP25*   *TIMP1*   *TIMP2*    *TIMP3*   *TIMP4*
  ------------------ ---------- --------- ---------- --------- --------- --------- --------- --------- --------- ---------- --------- ---------
  BaseMean           7918.05    37.645    10816.6    498.068   402.112   129.329   407.115   32.0523   3772.49   27817.6    7473.16   533.5
  Log2 FoldChange    5.26395    2.27464   4.13891    2.16889   −1.8413   −2.9409   3.71133   −1.8555   1.49335   2.10445    1.16444   1.77748
  LfcSE              0.69286    0.59681   0.40108    0.39237   0.40482   0.69567   0.4314    0.62099   0.35208   0.31444    0.39523   0.6906
  Stat               7.59742    3.81131   10.3194    5.52764   −4.5484   −4.2274   8.60299   −2.9879   4.24149   6.69264    2.94624   2.57382
  p Value            3E−14      0.00014   5.8E−25    3.2E−08   5.4E−06   2.4E−05   7.8E−18   0.00281   2.2E−05   2.2E−11    0.00322   0.01006
  Adjusted p value   8.4E−13    0.00057   6.5E−23    3.2E−07   3.2E−05   0.00012   3.8E−16   0.00802   0.00011   4E−10      0.00901   0.02403
  Control 1          182.645    0         275.352    117.612   711.21    395.731   16.6041   22.1388   599.132   8743.45    4679.59   253.213
  Control 2          453.634    13.9939   2239.02    141.105   928.26    165.594   45.4801   46.6462   3266.4    6040.69    2222.69   198.246
  Control 3          42.8228    0         1082.38    47.2527   218.544   160.955   57.5892   270.226   3397.76   6622.76    7322.69   243.647
  Control 4          224.35     0         213.81     213.81    2567.23   1075.08   30.1142   76.7911   1017.86   4381.61    3014.43   367.393
  Control 5          252.687    19.151    588.894    120.758   808.067   170.231   32.9823   26.0667   691.565   6271.96    3574.86   165.976
  Control 6          61.4008    20.4669   467.816    273.38    381.562   251.451   48.2435   58.4769   2150.49   12322.6    4942.76   0
  Control 7          96.9527    9.61515   1185.87    118.587   497.584   83.3313   18.429    26.4416   1578.49   10136      4299.57   92.9464
  Control 8          26.5541    6.88439   70.8108    63.9265   541.9     518.296   57.0421   21.6366   215.383   10492.8    1072      33.4385
  SEGA1              350.288    99.906    10408.7    1214.91   83.8717   3.70022   145.542   0         2070.89   8752.26    29806.5   477.329
  SEGA2              19 637.7   35.9809   27384.9    721.305   174.845   38.2298   278.29    12.9307   1977.83   59003.1    4009.06   558.267
  SEGA3              326.138    14.7288   25176.8    1391.87   131.507   0         193.579   7.36442   5079.34   36881      25576.6   26.3015
  SEGA4              170.591    28.7514   12355.4    1046.55   55.586    0.95838   208.927   17.2508   2749.59   28491.6    8542.03   411.144
  SEGA5              3984.96    62.718    17916.6    324.24    427.192   77.51     1091.06   21.8921   3878.46   51157.2    4553.56   186.971
  SEGA6              15 097.6   29.4384   12479.7    817.734   711.974   7.63219   390.332   6.54187   3086.67   41390.4    4661.08   757.767
  SEGA7              48 776.7   90.7741   20215.5    380.941   216.461   33.3614   443.785   0         3766.74   55441.3    6153.24   2215.04
  SEGA8              924.957    28.444    6737.01    243.354   92.7064   189.627   31.6044   4.21393   3188.89   29829.3    6329.32   51.6206
  SEGA9              1171.21    8.16435   12124.8    866.163   107.621   5.1955    235.282   27.4619   3664.31   40081.8    6475.81   565.567
  SEGA10             215.259    11.5576   1533.54    18.781    85.237    4.33408   1272.78   26.0045   9095.07   6490.29    3561.89   0
  SEGA11             1669.2     53.9765   14927.1    1188.5    250.533   99.8056   1758.82   42.7738   3814      39267.4    7084.16   89.6214
  SEGA12             31 142.2   17.1046   30274.5    599.319   276.305   3.94722   809.18    7.23657   2407.8    68810.6    1033.51   360.513
  SEGA13             5142.81    22.1056   7551.02    466.819   202.852   0         274.37    50.7129   6522.46   16450.5    10090.6   3808.67
  SEGA14             7749.68    11.8189   19932.6    424.3     87.4601   11.8189   579.128   0         5109.33   45514.7    9754.17   33.093
  SEGA15             444.297    56.1474   9724.48    961.829   69.5739   9.76476   281.957   4.88238   6996.45   18311.4    13725.6   86.6623
  SEGA16             13 231     11.3008   16272.1    386.488   479.155   75.7155   305.122   2.26017   2356.22   48061.3    2552.86   1237.44
  SEGA17             44 702.6   271.937   21 368.3   243.825   195.06    89.4982   523.794   12.0478   5108.28   57 122.2   16 237    1060.78
  SEGA18             4069.25    76.7546   12 831.9   469.336   211.39    20.1324   1323.7    22.6489   9297.37   13 926.6   5554.01   54.1057
  SEGA19             13 639.8   14.6952   6709.02    585.136   343.333   0         538.378   50.7652   8770.36   21 080.9   4945.6    1068.74

MMPs, matrix metalloproteinases; SEGA, subependymal giant cell astrocytomas; TIMPs, tissue-inhibitors of metalloproteinases.

MMP2 and MMP14 Protein Expression Increased in SEGA
---------------------------------------------------

As *MMP2* and *MMP14* had the most abundant RNA expression in SEGA compared to controls they were selected for further analysis at the protein level. To study cellular localization and distribution, and to quantify protein expression of MMP2 and MMP14 in SEGA, immunohistochemistry was performed on SEGA and periventricular control tissue slides ([Fig. 3A--F](#nlaa040-F3){ref-type="fig"}). In periventricular control tissue both MMP2 and MMP14 were not detected in glial cells in the wm. In nearby cortex tissue, low immunoreactivity of MMP2 and MMP14 was observed in neurons ([Fig. 3A, B](#nlaa040-F3){ref-type="fig"}). In SEGA, moderate to high immunoreactivity of MMP2 and MMP14 was found in giant cells ([Fig. 3C, D](#nlaa040-F3){ref-type="fig"}). The OD of MMP2 and MMP14 was higher in SEGA as compared to periventricular wm of controls ([Fig. 3F;](#nlaa040-F3){ref-type="fig"} p \< 0.05).

![Protein expression of MMP2, MMP14 in subependymal giant cell astrocytomas (SEGA). **(A--D)** A moderate to high immunoreactivity of MMP2 **(C)** and MMP14 **(D)** was observed in SEGA, while no to low immunoreactivity was seen in periventricular white matter (wm) and gray matter (gm) control tissue, respectively **(A, B)**. Insets show a higher magnification of giant cells (indicated with arrows) in SEGA. Scale bar: 100 µm; insets: 50 µm. **(E, F)** The optical density per case for the immunoreactivity of MMP2 **(E)** and MMP14 **(F)** in periventricular control tissue (n = 3/4) and SEGA (n = 4). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, Mann-Whitney U test.](nlaa040f3){#nlaa040-F3}

miR-320d as a Predictive Regulator of MMPs Is Expressed at Lower Levels in SEGA Compared to Control
---------------------------------------------------------------------------------------------------

To identify miRNAs that target *MMP2*, *MMP11*, *MMP14*, *MMP15*, and *MMP19*, differentially expressed miRNAs with a lower expression in SEGA as compared to controls were evaluated with miRWalk2. Based on small RNA-Seq data, we found 49 miRNAs with lower expression in SEGA as compared to controls. Six miRNAs (miR-320d, miR-320b, miR-320c, miR-625-5p, miR-330-5p, and miR-3200-3p) were predicted to target all 5 *MMPs* (*MMP2*, *MMP11*, *MMP14*, *MMP15*, and *MMP19*) with a higher expression in SEGA as compared to controls ([Fig. 4A](#nlaa040-F4){ref-type="fig"}). Spearman correlations using the RNA-Seq data were calculated between each miRNA and their predicted MMP target ([Table 4](#nlaa040-T4){ref-type="table"}). miR-320d showed the strongest negative correlation with all 5 *MMPs* (*MMP2*: R: −0.484, p = 0.010; *MMP11*: R: −0.459, p = 0.016; *MMP14*: R: −0.572, p = 0.002; *MMP15*: R: −0.471, p = 0.013; *MMP19*: R: −0.433, p = 0.024) and was therefore selected for further analysis. Using RT-qPCR the lower expression of miR-320d in SEGA as compared to control samples was validated ([Fig. 4B](#nlaa040-F4){ref-type="fig"}). To study the downregulation of miR-320d on a cellular level, in situ hybridization was performed ([Fig. 4C](#nlaa040-F4){ref-type="fig"}). In control tissue, miR-320d is abundant in glial cells in periventricular wm and neuronal cells, whereas in SEGA miR-320d was not detected. The OD of miR-320d was lower in SEGA as compared to controls ([Fig. 4D;](#nlaa040-F4){ref-type="fig"} p \< 0.05).

![miR-320d is a predictive regulator of MMPs and is lower expressed in subependymal giant cell astrocytomas (SEGA) compared to control. **(A)** Heatmap showing all underexpressed miRNAs in SEGA as compared to controls (adjusted p value \<0.05) predicted to target *MMP2*, *MMP11*, *MMP14*, *MMP15*, and/or *MMP19* (based on miRWalk2). Green boxes indicate *MMP19*, *MMP15*, *MMP14*, *MMP11*, and/or *MMP2* as predicted target of a specific miRNA. **(B)** Relative expression of miR-320d in SEGA (n = 12) as compared to control tissue (n = 8). Data are expressed relative to the expression observed in control tissue. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, Mann-Whitney U test. **(C)** In situ hybridization of miR-320d in periventricular white matter (wm) and gray matter (gm) control and SEGA tissue. Giant cells are indicated with arrows. Scale bar: 100 µm. **(D)** The optical density per case for the in situ hybridization signal of miR-320d in periventricular control tissue (n = 7/9) and SEGA (n = 8). \*p \< 0.05, \*\*\*p \< 0.001, Mann-Whitney U test.](nlaa040f4){#nlaa040-F4}

###### 

Correlations of*MMPs* and *TIMPs* With miR-320d, miR-320b, miR-320c, miR-625-5p, miR-330-5p, and miR-3200-3p

  MicroRNA→ Gene↓   miR-320d (p Value; r)   miR-320b (p Value; r)   miR-320c (p Value; r)   miR-625-5p (p Value; r)   miR-330-5p (p Value; r)   miR-3200-3p (p Value; r)
  ----------------- ----------------------- ----------------------- ----------------------- ------------------------- ------------------------- --------------------------
  *MMP2*            0.010; −0.484           0.028; −0.423           0.052; −0.379           0.243; −0.233             0.271; −0.22              0.493; −0.138
  *MMP11*           0.016; −0.459           0.024; −0.432           0.012; −0.477           0.03; −0.419              0.072; −0.351             0.062; −0.363
  *MMP14*           0.002; −0.572           0.024; −0.433           0.007; −0.503           0.019; −0.45              0.044; −0.391             0.061; −0.366
  *MMP15*           0.013; −0.471           0.028; −0.422           0.011; −0.481           \<0.001; −0.627           0.024; −0.433             \<0.001; −0.644
  *MMP16*           0.074; 0.349            0.315; 0.201            0.058; 0.37             0.021; 0.443              0.06; 0.367               0.004; 0.532
  *MMP17*           0.040; 0.397            0.058; 0.369            0.013; 0.47             0.002; 0.56               0.093; 0.33               \<0.001; 0.633
  *MMP19*           0.024; −0.433           0.083; −0.340           0.031; −0.416           0.168; −0.273             0.269; −0.22              0.518; −0.13
  *MMP25*           0.050; 0.380            0.125; 0.302            0.039; 0.399            0.095; 0.328              0.085; 0.337              0.202; 0.254
  *TIMP1*           0.372; −0.179           0.634; −0.096           0.403; −0.168           0.489; −0.139             0.565; −0.116             0.477; −0.143
  *TIMP2*           0.001; −0.590           0.014; −0.467           0.011; −0.483           0.034; −0.41              0.014; −0.466             0.084; −0.338
  *TIMP3*           0.348; −0.188           0.475; −0.143           0.275; −0.218           0.096; −0.327             0.073; −0.351             0.014; −0.467
  *TIMP4*           0.259; −0.225           0.102; −0.321           0.383; −0.175           0.308; −0.204             0.251; −0.229             0.099; −0.324

MMPs, matrix metalloproteinases; TIMPs, tissue-inhibitors of metalloproteinases.

Regulation of *MMP* by miR-320d Mimic Transfection in Fetal Astrocytes
----------------------------------------------------------------------

To study regulation of *MMP2*, *MMP11*, *MMP14*, *MMP15* and *MMP19* by miR-320d, fetal astrocytes were transfected with miR-320d mimic. RT-qPCR revealed that transfection with 50 nM miR-320d mimic led to a higher expression of miR-320d ([Fig. 5A;](#nlaa040-F5){ref-type="fig"} p \< 0.05). RNA expression of *MMP2*, *MMP11*, *MMP14*, *MMP15* and *MMP19* was determined 24 hours after miR-320d transfection using RT-qPCR, and showed a lower expression of *MMP2* in miR-320d mimic transfected cells compared to control ([Fig. 5B;](#nlaa040-F5){ref-type="fig"} p = 0.002), whereas the expression of *MMP11*, *MMP14*, *MMP15* and *MMP19* did not differ between conditions ([Fig. 5C--F](#nlaa040-F5){ref-type="fig"}).

![*MMP* expression after transfection with miR-320d in fetal astrocytes. (**A**--**F**) TaqMan PCR of miRNA-320d **(A)** and RT-qPCR of *MMP2* **(B)**, *MMP11* **(C)**, *MMP14* **(D)**, *MMP15* **(E)**, and *MMP19* **(F)** in fetal astrocytes transfected with miRNA-320d mimic (miR-320d) for 24 hours (n = 2 biological triplets and 3 technical duplicates). Data are normalized to lipofectamine (control). \*\*p \< 0.01, Mann-Whitney U test.](nlaa040f5){#nlaa040-F5}

DISCUSSION
==========

This study provides evidence that the MMP/TIMP proteolytic system is dysregulated in SEGA. We showed higher expression of *MMP2*, *MMP11*, *MMP14*, *MMP15*, *MMP19*, and their endogenous inhibitors *TIMP1*, *TIMP2* and *TIMP3* and lower expression of *MMP17* in SEGA as compared to periventricular control tissue. Furthermore, we identified the lowly expressed miR-320d in SEGA compared to controls as a potential MMP regulator that can decrease *MMP2* expression in vitro.

MMP and TIMP Expression in SEGA
-------------------------------

Dysregulation of ECM organization in TSC cortical tubers and SEGA has been suggested by several transcriptome studies showing differential expression of genes related to the gene ontology term ECM organization, however the ECM has not been studied in detail in SEGA ([@nlaa040-B24],[@nlaa040-B26],[@nlaa040-B27],[@nlaa040-B29]). In this study, we identified higher expression of *MMP2*, *MMP11*, *MMP14*, *MMP15*, *MMP16*, *MMP17*, *MMP19*, *MMP25*, *TIMP1*, *TIMP2* and *TIMP3* in SEGA as compared to controls. This suggests that the dysregulation of the MMP/TIMP proteolytic system is conserved across TSC pathology and might also affect migration during early brain development in TSC. In our previous study, we showed higher expression of MMPs and TIMPs in non-SEGA material of TSC patients. Among others, higher expression of *MMP2*, *MMP14*, *TIMP1*, *TIMP2* and *TIMP3* was observed in cortical tubers of TSC patients as compared to control cortex. Moreover, increased protein expression of MMP2 and MMP14 was also observed in tubers of TSC patients and the expression of MMPs and TIMPs was associated with neuroinflammation and BBB dysfunction ([@nlaa040-B28]). This indicates that the overexpression of MMPs might not be SEGA-specific, but it does underlie its relevance in the dysfunctional microenvironment that is present in TSC-related brain alterations. Multiple studies have shown the presence of neuroinflammation in TSC cortical tubers and SEGA ([@nlaa040-B24],[@nlaa040-B26],[@nlaa040-B27],[@nlaa040-B29],[@nlaa040-B62]). Previously, we have shown that the immune system is among the most represented enriched pathways in SEGA ([@nlaa040-B26]). Furthermore, upregulation of several cytokines, including interleukin 33, TNF Superfamily member 8, C-C Motif Chemokine Ligand 3, and C-C Motif Chemokine Ligand 5 was observed in SEGA compared to controls. Moreover, albumin extravasation, with uptake in astrocytes, has been reported in cortical tubers and SEGA of TSC patients, suggesting that alterations in BBB permeability are associated with the inflammation in TSC brain lesions ([@nlaa040-B62],[@nlaa040-B65]). MMPs can contribute to the inflammatory response by cleaving propeptides of cytokines such as TNFα and IL-1β, thereby activating them ([@nlaa040-B66]). In turn, neuroinflammation can increase the expression and activity of MMPs and infiltrating immune cells such as leukocytes, which are a major source of MMP9 ([@nlaa040-B69],[@nlaa040-B70]). The link between the neuroinflammation and MMPs in SEGA deserves further investigation.

MMPs are also known to be involved in cancer pathology in multiple ways, including intravasation and extravasation of tumor cells, migration of tumor cells in the brain and adhesion of metastatic cells to the ECM ([@nlaa040-B38]). Previous research has shown that higher *MMP2* expression can be a predictor for overall survival of patients with astrocytomas ([@nlaa040-B71]). In another study, it was found that *MMP14* and *MMP19* had higher expression in gliomas compared to healthy control tissue, and that coexpression of *MMP14* and *MMP19* predicted poor survival in human glioma ([@nlaa040-B72],[@nlaa040-B73]). Furthermore, a correlation between higher *MMP11* and *MMP19* expression and increased WHO-grading of malignant tumors has been suggested ([@nlaa040-B74]). However, SEGA are slow-growing, WHO grade I tumors that are not associated with poor survival rates, suggesting that in SEGA the higher MMP expression is most likely not linked to overall survival ([@nlaa040-B51]). Furthermore, in this study we did not find any correlation with the clinical traits investigated, including preoperative seizure frequency, duration of epilepsy, size of the tumor, and tumor recurrence/regrowth. A previous study found increased expression of TIMP1 and TIMP2 in grade I brain tumors compared to grade II or III tumors ([@nlaa040-B75]). Furthermore, it has been shown that TIMP2, is also involved in the activation of pro‐MMP2 together with MMP14 ([@nlaa040-B76],[@nlaa040-B77]). We found a higher expression of MMP inhibitors *TIMP1*, *TIMP2* and *TIMP3* in SEGA as compared to control tissue. The higher expression of *TIMPs* may act as a compensatory mechanism for higher *MMP* expression, which could explain why the higher expression of *MMP2*, *MMP11*, *MMP14*, *MMP15*, and *MMP19* does not lead to metastases and excessive growth in SEGA. Interestingly, we found that *MMP19* was highly expressed in recurrent/regrown SEGA as compared to nonrecurrent/regrown SEGA using RT-qPCR analysis. Previous studies found a correlation between *MMP19* expression and tumor malignance/invasion ([@nlaa040-B72],[@nlaa040-B74],[@nlaa040-B78]). Therefore, *MMP19* expression could potentially be utilized as a biomarker for recurrence/regrowth. However, our sample size of recurrent/regrown SEGA was small and this effect was not found in the RNA-Seq data, indicating that further investigation is required.

miR-320d Is a Predictive Regulator of MMPs and Is Expressed at Lower Levels in SEGA Compared to Control
-------------------------------------------------------------------------------------------------------

Previous research has shown the importance of miRNAs in TSC and SEGA ([@nlaa040-B26],[@nlaa040-B29]) and their role in regulating MMP expression ([@nlaa040-B28],[@nlaa040-B79]). In this study, we identified 6 miRNAs (miR-320d, miR-320b, miR-320c, miR-625-5p, miR-330-5p, and miR-3200-3p) with lower expression in SEGA as compared to controls that could potentially target MMP expression. Research from Qin et al ([@nlaa040-B49]) has shown that downregulation of miR-320d in gliomas predicted lower survival rates and increased growth and proliferation. However, in our study we did not find a correlation between the expression of miR-320d and the size of tumor or tumor recurrence/regrowth. Furthermore, Qin et al ([@nlaa040-B49]) indicated miR-320d as a regulator of *MMP2*, decreasing MMP2 protein expression in glioma cell lines, inducing cell apoptosis and suppressing cell growth and migration. In accordance with this study, we found that miR-320d can target *MMP2* in human fetal astrocytes, but did not affect the expression of *MMP11*, *MMP14*, *MMP15*, and *MMP19*. Since the interaction of miR-320d was based on prediction tools, it could be that these MMPs are not responsive to this miRNA, however, further investigation is needed. Alternatively, it could be of interest to combine miR-320d with the other 5 miRNAs predicted to target *MMP2*, *MMP11*, *MMP14*, *MMP15* and *MMP19* (miR-320b, miR-625-5p, miR-320c, miR-330-5p, and miR-3200-3p) to increase the regulatory effect on MMP expression.

Taken together, this study provides evidence that both MMPs and TIMPs are highly expressed in SEGA compared to control tissue, indicating that the MMP/TIMP proteolytic system is dysregulated in SEGA as observed in tubers of TSC patients. The MMP-targeting miR-320d is downregulated in SEGA. In human fetal astrocytes, the dysregulation of *MMP2* can be normalized by miR-320d. We therefore conclude that targeting *MMPs* potentially with miR-320d alone or in combination with other *MMP* targeting miRNAs could be of interest as a therapeutic intervention for TSC patients with SEGA.

Supplementary Material
======================
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Click here for additional data file.
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